Monocyte Chemotactic Protein 2

Monocyte Chemotactic Protein 2 (MCP-2)

Monocyte Chemotactic Protein 2 (MCP-2; CCL8), is a chemotactic factor that attracts monocytes, lymphocytes, basophils and eosinophils. MCP-2 may play a role in neoplasia and inflammatory host responses. This protein can bind heparin. The processed form MCP-2(6-76) does not show monocyte chemotactic activity, but inhibits the chemotactic effect most predominantly of CCL7, and also of CCL2 and CCL5 and CCL8. Highest expression of MCP-2 is found in the small intestine and peripheral blood cells. Intermediate levels seen in the heart, placenta, lung, skeletal muscle, thymus, colon, ovary, spinal cord and pancreas. Low levels seen in the brain, liver, spleen and prostate. It is induced by IFNG/IFN-gamma, mitogens, and IL-1.

Swiss-Prot Accession Number: P80075

Publications

Amygdalar activity predicts future incident diabetes independently of adiposity (2019) Osborne MT, Ishai A, Hammad B, Tung B, Wang Y, Baruch A, Fayad ZA, Giles JT, Lo J, Shin LM, Grinspoon SK, Koenen KC, Pitman RK, Tawakol A Psychoneuroendocrinology

Inflammatory parameters associated with systemic reactogenicity following vaccinatino with adjuvanted hepatitis B vaccines in humans (2019) Burny W, Marchant A, Herve C, Callegaro A, Caubet M, Fissette L, Gheyle L, Legrand C, Ndour C, Tavares Da Silva F, van der Most R, Willems F, Didierlaurent AM, Yarzabal J, ECR-008 study group Vaccine

Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment (2018) van den Ham HJ, Cooper J, Tomasik J, Bahn S, Aerts J, Oseterhaus A, Gruters R, Andeweg A PLoS One

High false-positive rate of a putative biomarker test to aid in the diagnosis of schizophrenia (2016) Wehler CA, Preskorn, SH Journal of Clinical Psychiatry

Variation in Serum Biomarkers with Sex and Female Hormonal Status: Implications for Clinical Tests (2016) Ramsey JM, Cooper JD, Penninx BWJH, Bahn S Scientific Reports

Inflammatory Molecular Signature Associated With Infectious Agents in Psychosis (2014) Hayes LN, Severance EG, Leek JT, Gressitt KL, Rohleder C, Coughlin JM, Leweke FM, Yolken RH, Sawa A Schizophr Bull. 2014 Apr 17. [Epub ahead of print]

Predicting therapeutic efficacy of intravenous immunoglobulin (IVIG) in individual patients with relapsing remitting multiple sclerosis (RRMS) by functional genomics (2014) Berger T, Jacob C, Haas J, Ransmayr G, Guger M, Zettl UK, Di Pauli F, Taumberger B, Wietek S, Meuer S, Reindl M, Giese T Journal of Neuroimmunology DOI: 10.1016/j.jneuroim.2014.10.001

Validation of a Blood-Based Laboratory Test to Aid in the Confirmation of a Diagnosis of Schizophrenia (2010) Schwarz E, Izmailov R, Spain M, Barnes A, Mapes JP, Guest PC, Rahmoune H, Pietsch S, Leweke FM, Rothermundt M, Steiner J, Koethe D, Kranaster L, Ohrmann P, Suslow T, Levin Y, Bogerts B, (JM) van Beveren N, McAllister G, Weber N, Niebuhr D, Cowan D, Yolken RH, Bahn S Biomark Insights5: 39–47.